Compare RGNX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNX | ABSI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 357.9M |
| IPO Year | 2015 | 2021 |
| Metric | RGNX | ABSI |
|---|---|---|
| Price | $8.38 | $3.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $28.75 | $7.47 |
| AVG Volume (30 Days) | 794.1K | ★ 3.8M |
| Earning Date | 03-05-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | $4,534,000.00 |
| Revenue This Year | $50.05 | $640.57 |
| Revenue Next Year | $23.31 | $71.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.04 | $2.01 |
| 52 Week High | $16.19 | $5.23 |
| Indicator | RGNX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 56.25 |
| Support Level | $7.81 | $2.45 |
| Resistance Level | $9.28 | $3.26 |
| Average True Range (ATR) | 0.47 | 0.24 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 46.82 | 80.31 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.